Actemra/RoActemra is approved in 116 countries for the treatment of rheumatoid arthritis (RA). It is also approved for the treatment of paediatric juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA), giant cell arteritis (GCA) and CAR-T cell-induced cytokine release syndrome (CRS). Actemra/RoActemra is available in both subcutaneous (SC) and intravenous (IV) formulations.
Actemra/RoActemra is a first-in-class anti-IL-6 receptor (aIL-6R) therapy. IL-6 is believed to play a key role in activating the inflammatory pathway that contributes to the signs and symptoms of RA and other inflammatory autoimmune conditions. Actemra/RoActemra binds to IL-6 receptors, blocking the pro-inflammatory effect of IL-6 cytokines.